Q-omics provides the consensus-scored KRT8P11 profile across patient tissues and cancer cell-line models. KRT8P11 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, KRT8P11 is differentially expressed in 10, with the highest sampling consensus in KIRP. Additionally, KRT8P11 RNA expression shows 12,746 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, KIRP, and TGCT as cancer lineages where KRT8P11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT8P11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT8P11 survival associations across molecular data types. KRT8P11 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT8P11 RNA expression–survival associations across cancer types. High KRT8P11 expression shows unfavorable associations in UCEC, OV, COAD, MESO and LIHC, but favorable associations in ACC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify UCEC as the clearest survival context for KRT8P11 RNA expression.
This table summarizes KRT8P11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for KRT8P11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT8P11 shows lower tumor expression in COAD and THCA and higher tumor expression in KIRP, LUAD, STAD and BRCA. The KIRP box plot shows higher KRT8P11 RNA expression in tumor versus normal tissue (log2 FC = +0.855, t-test p < 0.001).
This table shows molecular features associated with KRT8P11 in patient tissues and cancer cell lines. In patient samples, KRT8P11 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
